HeartBeam (NASDAQ: BEAT) has been recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics, ranking second worldwide in 12-lead ECG innovation among 243 firms analyzed, according to PatentVest’s “Total Cardiac Intelligence” report. The company trails only GE Healthcare, underscoring the rapid maturation of its proprietary synthesis-ECG system. This technology captures the heart’s electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG, allowing physicians to obtain cardiologist-level data from compact devices usable far from traditional hospital settings.
The recognition highlights HeartBeam’s growing influence in next-generation cardiac monitoring technology. The company’s approach addresses a persistent challenge in modern medicine: delivering high-quality cardiac monitoring for arrhythmia assessment wherever patients are. HeartBeam is currently cleared for arrhythmia detection, with ischemia detection as a future goal. The system’s ability to provide actionable heart intelligence from portable devices could redefine cardiac health management by enabling early identification of cardiac trends and acute conditions outside medical facilities.
HeartBeam holds 13 U.S. and four international-issued patents related to its technology enablement. The company is creating the first-ever cable-free 12-lead ECG capable of capturing electrical signals from three dimensions, designed for use in portable devices that can be used wherever the patient is. This platform technology aims to deliver powerful cardiac insights and direct patients to appropriate care, reducing reliance on hospital-based diagnostics.
The full article detailing HeartBeam’s ranking is available at https://ibn.fm/3ADRP. For more information about HeartBeam, visit www.HeartBeam.com. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
